Skip to main content

Table 4 Multivariable linear regression evaluating association between MAP values while receiving vasopressors and trial initiation

From: The evolution of mean arterial pressure in critically ill patients on vasopressors before and during a trial comparing a specific mean arterial pressure target to usual care

Trial initiation defined by a dichotomous variable (pre-trial vs. during-trial periods) Trial initiation defined by a three-category variable (pre-trial period, non-enrolled group, usual care control group)
Variable β coefficient 95% Confidence interval p-value Variable β coefficient 95% Confidence interval p-value
During-trial period
(Non-enrolled + Usual care control groups)
0.47 (− 0.85, 1.80) 0.48 Non-enrolled group 0.66 (− 0.68, 2.00) 0.33
Usual care control group 2.35 (−0.11, 4.82) 0.06
Pre-trial period Reference Pre-trial period Reference
APACHE II, per 10-point increase −0.07 (−0.13, − 0.01) 0.03 APACHE II, per 10-point increase − 0.06 (− 0.12, − 0.001) 0.04
Chronic hypertension (yes) −0.71 (−1.72, 0.31) 0.17 Chronic hypertension (yes) −0.71 (−1.72, 0.31) 0.17
Age, per 5-year increase −0.03 (−0.1, 0.03) 0.32 Age, per 5-year increase −0.05 (−0.12, 0.02) 0.18
Site 1 −1.22 (−2.61, 0.16) 0.08 Site 1 −1.11 (−2.49, 0.27) 0.11
Site 2 −1.32 (−2.96, 0.31) 0.11 Site 2 −1.32 (−2.94, 0.30) 0.11
Site 3 1.01 (−0.66, 2.68) 0.24 Site 3 1.17 (−0.49, 2.83) 0.17
Site 5 5.63 (2.05, 9.22) 0.002 Site 4 Reference
Site 4 Reference
Time from trial initiation to hospital admission −0.001 (−0.005, 0.002) 0.39 Time from trial initiation to hospital admission −0.004 (−0.009, 0.0004) 0.07
  1. The 2-group analysis includes 429 patients from five sites. The three-group analysis include 419 patients from four sites, because the fifth site did not enroll any patients in the trial. Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II score